Authorized purpose: The red dot software platform is a software workflow tool designed to aid the clinical assessment of adult chest X-Ray cases with features suggestive of Pneumothorax in the medical care environment. Red dot analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. red dot is not intended to direct attention to specific portions basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Clinical role
Triage software that automatically analyzes PA/AP chest X-rays and sends a passive notification through the PACS/RIS workstation to radiologists for prioritization of cases suggestive of pneumothorax, in parallel to standard of care, without marking images or removing cases.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: red dot™ is not intended to direct attention to specific portions of an image or to anomalies other than Pneumothorax. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The red dot software platform is a software workflow tool designed to aid the clinical assessment of adult chest X-Ray cases with features suggestive of Pneumothorax in the medical care environment. Red dot analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. red dot is not intended to direct attention to specific portions basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: PA/AP chest x-rays
Who uses it?Intended users: Radiologist
What does the software produce?Output: The device provides a case-level passive notification/flag to the PACS/RIS/workstation worklist indicating the existence of a chest X-ray case that may potentially benefit from prioritization due to features suggestive of pneumothorax. It does not output an image, does not mark or highlight specific locations, and does not provide a definitive diagnosis.
What is its most important limitation?Key limitation: red dot™ is not intended to direct attention to specific portions of an image or to anomalies other than Pneumothorax. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Clinical takeaway. Clinical role: The red dot software platform is a software workflow tool designed to aid the clinical assessment of adult chest X-Ray cases with features suggestive of Pneumothorax in the medical care environment. Red dot analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. red dot is not intended to direct attention to specific portions basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The red dot software platform is a software workflow tool designed to aid the clinical assessment of adult chest X-Ray cases with features suggestive of Pneumothorax in the medical care environment. Red dot analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. red dot is not intended to direct attention to specific portions basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Triage software that automatically analyzes PA/AP chest X-rays and sends a passive notification through the PACS/RIS workstation to radiologists for prioritization of cases suggestive of pneumothorax, in parallel to standard of care, without marking images or removing cases.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The software automatically analyzes PA/AP chest x-rays and alerts the PACS/RIS workstation once images with features suggestive of pneumothorax are identified." … "the red dot™ device provides a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from prioritization.". Read from the exact FDA decision document on 2026-11-14.
The device provides a case-level passive notification/flag to the PACS/RIS/workstation worklist indicating the existence of a chest X-ray case that may potentially benefit from prioritization due to features suggestive of pneumothorax. It does not output an image, does not mark or highlight specific locations, and does not provide a definitive diagnosis.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
red dot™ is not intended to direct attention to specific portions of an image or to anomalies other than Pneumothorax. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Exact FDA submission
Checked 2026-09-19
The exact indication states the output-use, diagnostic-decision, and clinical-assessment limits.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
red dot regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K191556
Samplen=888
Sites4
IndependenceIndependence not established
K191556
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K191556. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: PA/AP chest x-rays
Scope: Exact FDA submission. The exact device description identifies the analyzed images as PA/AP chest x-rays.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: The device provides a case-level passive notification/flag to the PACS/RIS/workstation worklist indicating the existence of a chest X-ray case that may potentially benefit from prioritization due to features suggestive of pneumothorax. It does not output an image, does not mark or highlight specific locations, and does not provide a definitive diagnosis.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The device provides a case-level passive notification/flag to the PACS/RIS/workstation worklist indicating the existence of a chest X-ray case that may potentially benefit from prioritization due to features suggestive of pneumothorax. It does not output an image, does not mark or highlight specific locations, and does not provide a definitive diagnosis.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K191556 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.